Literature DB >> 17388703

Early prediction of antipsychotic nonresponse among patients with schizophrenia.

Stefan Leucht1, Raymonde Busch, Werner Kissling, John M Kane.   

Abstract

OBJECTIVE: Schizophrenia guidelines recommend waiting several weeks before major changes in antipsychotic treatment are implemented. If, however, nonresponders could be identified shortly after treatment initiation, considerable time could be saved by rapidly switching such patients to potentially more effective alternatives. We therefore attempted to identify what degree of nonresponse shortly after initiation of antipsychotic drug treatment predicts nonresponse at 4 weeks.
METHOD: Individual patient data from 7 randomized, controlled antipsychotic drug trials including 1708 patients with schizophrenia or schizophreniform disorder according to DSM-III-R or DSM-IV criteria and positive symptoms (mean +/-SD age of 36.0 +/-10.9 years; 1054 men and 654 women) were pooled. Receiver-operator curves and logistic regression analyses were used to predict nonresponse at week 4 from the percentage Brief Psychiatric Rating Scale (BPRS) score change at weeks 1 and 2. Three criteria for nonresponse at week 4 were examined: less than 25% BPRS score reduction, less than 50% BPRS score reduction, and "no remission."
RESULTS: Cutoffs predicting nonresponse at 4 weeks with 90% specificity were virtually no response at week 1 (less than 3%-7% BPRS score reduction) and less than 15%, 25%, and 20% at week 2 for the 3 nonresponse criteria described above, respectively. However, to predict less than 25% BPRS score reduction with a positive predictive value of 80%, the cutoff needed was 0% BPRS score reduction at week 2. When the cutoffs identified were entered in logistic regression analyses together with other parameters, they remained the strongest predictors of nonresponse.
CONCLUSIONS: Patients with no improvement of symptoms during the first 2 weeks of treatment are unlikely to respond at week 4 and may benefit from a change of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388703     DOI: 10.4088/jcp.v68n0301

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Authors:  Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

3.  Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.

Authors:  Deepak K Sarpal; Miklos Argyelan; Delbert G Robinson; Philip R Szeszko; Katherine H Karlsgodt; Majnu John; Noah Weissman; Juan A Gallego; John M Kane; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2015-08-28       Impact factor: 18.112

4.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?

Authors:  Philip D Harvey; Alan S Bellack
Journal:  Schizophr Bull       Date:  2009-01-06       Impact factor: 9.306

5.  Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.

Authors:  Bruce J Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L Stauffer; Sara Kollack-Walker; Wei Zhou; Shitij Kapur; John M Kane
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

6.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

7.  Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.

Authors:  André Tadić; Stanislav Gorbulev; Norbert Dahmen; Christoph Hiemke; Dieter F Braus; Joachim Röschke; Dietrich van Calker; Daniel Wachtlin; Kai Kronfeld; Thorsten Gorbauch; Monika Seibert-Grafe; Klaus Lieb
Journal:  Trials       Date:  2010-02-26       Impact factor: 2.279

Review 8.  Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Authors:  Christoph Hiemke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

9.  Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Authors:  Allen W Nyhuis; Douglas E Faries; Haya Ascher-Svanum; Virginia L Stauffer; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2010-09-28       Impact factor: 3.630

10.  Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Authors:  Douglas E Faries; Allen W Nyhuis; Haya Ascher-Svanum
Journal:  Cost Eff Resour Alloc       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.